Investor Presentaiton

Oncology Pipeline Summary: 18 Assets in Pipeline under Development (3 products launched, 15 assets in clinical trials) Oncology Pipeline IBI-308 (PD-1) IBI-301 (CD20) IBI-305 (VEGF-A) IBI-310 (CTLA-4) IBI-102 (GITR) IBI-188 (CD47) IBI-101 (OX40) IBI-110 (LAG-3) IBI-939 (TIGIT) IBI-375 (FGFR1/2/3) IBI-376 (PI3K8) Innovent N=C-BH3 HC HCN NC BH3 MANTIBODY SMALL MOLECULE H NEC B BISPECIFIC ANTIBODY SHS CAR-T CARC CAR T cell Confidential Copyright©2021 Innovent Biologics IBI-318 (PD-1/PD-L1) IBI-315 (PD-1/HER2) IBI-319 (PD-1/4-1BB) IBI-321 (PD-1/TIGIT) Roche partnership BsAb IBI-322 (PD-L1/CD47) IBI-323 (LAG-3/PD-L1) Tumor cell IBI-326 (fully human BCMA CAR-T) Roche partnership 15

View entire presentation